This is an extension study of LON002 in patients with cancer, who have completed other London Pharma sponsored LON002 studies (parent study). It provides the opportunity for patients to continue receiving treatment for as long as the patient continues to derive a clinical benefit.~Long term safety and efficacy will be evaluated.
The purpose of this clinical trial is to evaluate the long term safety and efficacy of LON002.